The first irreversible BTK kinase inhibitor PCI-32765, which has demonstrated the proof-of-concept for the anti-arthritis efficacy by direct inhibition of BTK kinase, also bears potent activities against BLK, BMX, EGFR, Her2, ITK, JAK3, TEC and others9–11. The gene discussed is EGFR; the disease is Arthritis.